Showing 15 posts of 194 posts found.


Gilead’s Biktarvy proves non-inferior to standard care for HIV in Black and African American patients

October 22, 2020
Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has revealed promising new Phase 3 data reinforcing the non-inferiority of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg) compared to …


ViiV Healthcare secures FDA approval for Rukobia combo in multidrug-resistant HIV-1

July 6, 2020
Sales and Marketing FDA, HIV, ViiV Healthcare

ViiV Healthcare, the HIV specialist majority owned by GSK which also counts Shionogi and Pfizer among its shareholders, has secured …


Florida approve plan to release 750 million genetically modified mosquitoes to stop the spread of disease

June 19, 2020
Medical Communications AIDS, HIV, mosquitoes

Florida state regulators have gained approval to release 750 million genetically modified mosquitoes across the state to reduce the spread …


ViiV Healthcare scores world-first approval in Canada for monthly HIV regimen Cabenuva

March 23, 2020
Sales and Marketing Cabenuva, Canada, HIV, pharma

ViiV Healthcare has secured its first global approval for its once-monthly treatment Cabenuva, it has emerged, to replace current antiretroviral …

A man from London becomes second person to be cured of HIV

March 11, 2020
Research and Development HIV, HIV AIDS, HIV Drug, HIV cure, HIV/AIDS, anti-HIV

Adam Castillejo is the second man to be cured of HIV, after being free of the virus for more than …


Anti-HIV drug PrEP has 30% lower concentration levels in pregnant African adolescents and young women

March 10, 2020
Manufacturing and Production AIDS, HIV, PrEP, PrEP HIV, insulin

Pregnant African adolescents and young women who took the HIV drug PrEP were found to have 30% lower levels of …


Uganda finalising clinical trials on new injectable HIV drug

March 9, 2020
Sales and Marketing AIDS, HIV, Uganda HIV, Uganda HIV/AIDS, uganda

Uganda is preparing to enter the final stages of developing a new HIV treatment to reduce stigma and discrimination of …


Lack of mental health treatment available for HIV patients in the UK

March 6, 2020
Medical Communications AIDS, HIV, HIV AIDS, HIV treatment, HIV/AIDS

A cross-party group of MPs have said that those with HIV do not have access to adequate mental health treatment. …


Rapid testing to help combat worst UK outbreak of HIV in 30 years

February 18, 2020
Manufacturing and Production AIDS, HIV, HIV England, HIV Scotland, HIV epidemic, HIV/AIDS

New HIV tests that provide results in minutes are being used in Glasgow to fight a recent outbreak of HIV. …


Funding cuts and government inaction has led to soaring STI rates in Britain, new study finds

February 5, 2020
Research and Development AIDS, HIV, STDs, STIs, UK, sexual health

The UK faces a new Sexually Transmitted Infection (STI) diagnoses every 70 seconds, according to a new report that outlines …

National Institutes of Health terminates HIV vaccine after it proves ineffective

February 4, 2020
Manufacturing and Production HIV, pharma

A trial investigating the efficacy  of a new HIV vaccine conducted by the National Institute of Allergy and Infectious Diseases …

HIV infections fall by 73% in bi and gay British men

January 16, 2020
Business Services AIDS, AIDS Epidemic, HIV, NHS, NHS England, PrEP, nhs scotland

Public Health England has released figures that show that HIV rates in bi and gay men have fallen by 73% …


SMC gives nod for access to new HIV treatment Dovato

September 10, 2019
Manufacturing and Production HIV, SMC

The Scottish Medicines Consortium (SMC) has approved Dovato (dolutegravir/lamivudine) for use on the NHS, allowing treatment of individuals with a …


Gilead challenges Government over patents on preventative HIV drug Truvada

August 22, 2019
Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents

Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …

Latest content